Catridecacog, sold under the brand name Tretten in the US and NovoThirteen in the EU, is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.